Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 15/20 | 0.86 |
| ▸ | FAAH | O00519 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5055304 | 0.96 | HCAR2 (0.78) | HCAR2FAAHKDM4EALDH1A1HPGD | |
| SCHEMBL5055256 | 0.93 | HCAR2 (1.00) | HCAR2FAAH | |
| SCHEMBL5277092 | 0.90 | HCAR2 (0.70) | HCAR2FAAHKDM4EALDH1A1HPGD | |
| SCHEMBL13666109 | 0.89 | HCAR2 (1.00) | HCAR2FAAH | |
| SCHEMBL13666064 | 0.86 | HCAR2 (0.78) | HCAR2FAAHKMT2AL3MBTL1MAPT | |
| SCHEMBL13666121 | 0.86 | HCAR2 (0.66) | HCAR2FAAHKDM4EALDH1A1HPGD | |
| SCHEMBL12671399 | 0.84 | HCAR2 (1.00) | HCAR2FAAH | |
| SCHEMBL13666072 | 0.84 | HCAR2 (1.00) | HCAR2FAAH | |
| SCHEMBL13666082 | 0.84 | HCAR2 (1.00) | HCAR2FAAHKDM4EALDH1A1HSD17B10 | |
| SCHEMBL13666138 | 0.84 | HCAR2 (0.86) | HCAR2FAAHKDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080139565-A1 | Anthranilic Acid Derivatives and Their Use in Treatment of Diseases of Lipid Metabolism, in Particular Dyslipidaemia | SMITHKLINE BEECHAM CORPORATION | 2008-06-12 | — | — | US | disclosed |
| EP-1848707-A1 | AWTHRANILIC ACID DERIVATIVES AND THEIR USE IN TREATMENT OF DISEASES OF LIPID METABOLISM, IN PARTICULAR DYSLIPIDAEMIA | SMITHKLINE BEECHAM CORPORATION (US) | 2007-10-31 | — | — | EP | disclosed |
| WO-2006085108-A1 | AWTHRANILIC ACID DERIVATIVES AND THEIR USE IN TREATMENT OF DISEASES OF LIPID METABOLISM, IN PARTICULAR DYSLIPIDAEMIA | SMITHKLINE BEECHAM CORPORATION (US) | 2006-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139565-A1 | Anthranilic Acid Derivatives and Their Use in Treatment of Diseases of Lipid Metabolism, in Particular Dyslipidaemia | ANTXR2, CYP46A1, HCAR1 | HCAR2 16/4885FAAH 361/4885KDM4E 3897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.